Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program

The $3 billion deal will accelerate development of SNV4818, a potentially best-in-class cancer treatment.

Mar. 20, 2026 at 7:03am

Got story updates? Submit your updates here. ›

Synnovation Therapeutics, a clinical-stage biotech company, has agreed to sell its PI3Kα inhibitor program, including the lead candidate SNV4818, to pharmaceutical giant Novartis for up to $3 billion. SNV4818 is currently in Phase 1/2 trials for treating HR+/HER2- metastatic breast cancer and other solid tumors. Novartis will be responsible for future development and commercialization of the program, while Synnovation will retain ownership of its other R&D subsidiaries and continue advancing its pipeline independently.

Why it matters

The acquisition reflects Novartis's commitment to expanding its oncology portfolio with promising targeted therapies. For Synnovation, the deal provides significant resources to accelerate the development of SNV4818, which has the potential to become a best-in-class treatment for PI3Kα mutation-driven cancers. The transaction also validates Synnovation's drug discovery and development capabilities.

The details

Under the terms of the agreement, Novartis will pay Synnovation $2 billion upfront in cash, plus up to $1 billion in additional development, regulatory, and commercial milestone payments. Synnovation will retain ownership of its other research and development subsidiaries, while Novartis will be solely responsible for future development and commercialization of SNV4818 and other PI3Kα inhibitor programs. The transaction is expected to close in the first half of 2026, pending antitrust review.

  • The transaction is expected to be finalized in the first half of 2026.
  • SNV4818 is currently in Phase 1/2 clinical trials.

The players

Synnovation Therapeutics, LLC

A clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology.

Novartis

An innovative medicines company that works to reimagine medicine to improve and extend people's lives.

Wenqing Yao, Ph.D

Chief Executive Officer of Synnovation.

SNV4818

A potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase 1/2 clinical trials for the treatment of HR+/HER2- metastatic breast cancer and other solid tumors.

Got photos? Submit your photos here. ›

What they’re saying

“We believe Novartis's global capabilities and commitment to patients with cancer will accelerate the development of SNV4818 for patients with PI3Kα mutation–driven solid tumors beyond what Synnovation could achieve alone.”

— Wenqing Yao, Ph.D, Chief Executive Officer of Synnovation

What’s next

The transaction is expected to be finalized in the first half of 2026, pending antitrust review.

The takeaway

This acquisition highlights Novartis's strategic focus on expanding its oncology pipeline with promising targeted therapies, while also validating Synnovation's drug discovery and development capabilities. The deal provides significant resources to accelerate the development of SNV4818, a potentially best-in-class treatment for PI3Kα mutation-driven cancers.